Browse by Medical Category
David N. Louis, MD
Benjamin Castleman Professor of Pathology, Harvard Medical SchoolPathologist-in-Chief, Massachusetts General Hospital
Pathology ServiceMassachusetts General Hospital55 Fruit Street (WRN-2)Boston, MA 02114
Over the past 25 years, we have demonstrated alterations characteristic of specific glioma subtypes and grades. We originally demonstrated that molecular genetic analysis could be used to define clinicopathologically relevant subsets of glioblastomas, and then showed that molecular genetic alterations are powerful predictors of therapeutic response and survival in patients with anaplastic oligodendrogliomas and in other oligodendroglial tumors. These findings have already led to incorporation of molecular diagnostic testing around the world for these parameters. Work over the past few years has been directed toward incorporating molecular testing into the World Health Organization Classification of Central Nervous System Tumors, a process directed by Dr. Louis, and toward making molecular diagnostics a practical and routine part of brain tumor diagnosis. The lab has also demonstrated that glioblastomas treated with the alkylating agent temozolomide (which is now the standard of care for such cases) frequently inactivate mismatched repair genes, leading to more rapid growth during therapy and to therapeutic resistance, and has worked collaboratively on epigenetic and single-cell studies of high-grade gliomas.
Read more about the Louis Lab from the Center for Cancer Research Annual Report and the Pathology Basic Science Research Brochure.
David LouisR.K. NarayananSophie ShnaperMario SuvaJames KimBen Levin
Read about and apply for residency, fellowship and observership programs at http://www.massgeneral.org/pathology/training/.
Apply for temporary positions (summer interns) through the Mass General Careers Web site.
All applicants should register with the Mass General Careers Web site at http://www.massgeneral.org/careers/viewall.aspx.
Bibliography of David N. Louis via PubMed
WHO Classification of Tumours of the Central Nervous System, Revised. Fourth Edition 2016
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K. (Not yet in PubMed)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. Acta Neuropathol. 2016 Jun;131(6):803-20.
The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. Tanboon J, Williams EA, Louis DN. J Neuropathol Exp Neurol. 2016 Jan;75(1):4-18. Review
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P; International Society Of Neuropathology--Haarlem. Brain Pathol. 2014 Sep;24(5):429-35.
Massachusetts General Hospital
Back to Top